RE:RE:RE:RE:RE:ONCY's bought deal to support 2 Phase 3 studiesSo having ONCY move forward on conducting 2 Phase 3 clinical trials and then achieving 2 Accelerated Approvals on its own, only adds further value to ONCY as a fully operationally I/O bio-platform company, with 2 approved indications arising from its platform technology in pelareorep. Such a scenario would make highly valued and sought after by the same Big Pharma companies that we have been posting about as potential acquirers of ONCY.